Pharma & Healthcare
Soliris
Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its…
- Types
- Plasma Exchange · Plasma Infusion
- Applications
- PNH · aHUS · Other
5 editions30 December 2025
$4,950Single user · USD · Market Analysis & ForecastExplore product: SolirisCompare research options for Soliris